Incidence of febrile neutropenia with adjuvant docetaxel and cyclophosphamide in patients with early breast cancer.

SUMMARY Aim: To determine the incidence of febrile neutropenia (FN) associated with the use of docetaxel and cyclophosphamide (TC) as adjuvant chemotherapy for early breast cancer (EBC) and also the grade of neutropenia after cycle 1 of TC. Methods: We conducted a multicenter retrospective audit of women with EBC treated with TC between January 2010 and July 2011, recruited from seven Australian centers. Results: Of a total of 368 previously untreated women with EBC who received TC, 300 were evaluable for FN and 304 were evaluable for neutropenia after cycle 1 of TC. Overall, 73 (24.3%) patients developed FN. The incidence of FN was highest after cycle 1 of TC and was significantly higher in women under 65 years of age (p = 0.007). There was significant variation in the incidence of FN between participating sites (p < 0.001). Eight patients (2.6%) developed grade 3 neutropenia and 191 patients (62.8%) developed grade 4 neutropenia. Conclusion: TC as adjuvant chemotherapy for EBC is associated with a 24.3% incidence of FN and a 65.4% incidence of grade 3 or 4 neutropenia. The high incidence of FN and severe neutropenia warrant the use of G-CSF as primary prophylaxis.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Incidence of febrile neutropenia with adjuvant docetaxel and cyclophosphamide in patients with early breast cancer.

Cited by 3 publications

References 0 publications

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review

Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required

Contact Info

Product

Resources

About